Hydroxyapatite crystal nucleation

Hydroxyapatite crystal nucleation is the initial phase of hydroxyapatite formation, in which calcium and phosphate ions begin to assemble into the crystalline phase of hydroxyapatite, the principal inorganic component of bone and teeth[2][3][1]. This process is tightly regulated by multiple proteins such as bone sialoprotein (BSP), dentin phosphophoryn (DPP), osteocalcin (OC), osteopontin (OPN), and osteonectin (ON), which may either nucleate (initiate) or inhibit hydroxyapatite formation depending on their concentration and structural context[3][4][1]. Nucleation typically occurs upon protein matrices like collagen or silk proteins, which provide a structural template, and is sensitive to the physicochemical environment (pH, ion concentration, presence of modifiers like amino acids or small molecules)[1][3][6]. Hydroxyapatite crystal nucleation is fundamentally a physicochemical event with essential biological consequences for bone strength, growth, and repair, but it is not a receptor, enzyme, or druggable molecular target in the classic sense. Therefore, "Hydroxyapatite crystal nucleation" is not considered a therapeutic target, but rather a biological process susceptible to modulation by therapeutic agents (e.g., bisphosphonates or biomolecule mimics)[3][4]. Summary of issues: - This entry refers to a process, not to a defined molecule, receptor, or gene product. - It is not classified within pharmacological target families (receptor, enzyme, transporter, etc.) and cannot be mapped to a primary structure, gene, or protein. - Therapeutic interventions act on the process or its organic mediators rather than on "hydroxyapatite crystal nucleation" itself[3][4][1]. References for context and details: [1]: Explains the role of proteins and their structures in nucleating HAP in a biomimetic environment. [2]: Describes HAP as a mineral phase in bone, discusses crystal structure, and mentions nucleation in biological contexts. [3]: Focuses on the modulatory effects of amino acids and charged residues on HAP nucleation and growth. [4]: Details how different mineralization-regulating proteins can nucleate or inhibit HAP formation and at what concentrations. [6]: Mentions studies of nucleation on collagen matrices.

Other names

HAP nucleationHydroxyapatite nucleationHA crystal formationApatite mineralization

Inhibition of crystal growth by binding crystal faces (e.g., bisphosphonates, pyrophosphate analogs) Protein-mediated nucleation or inhibition (proteins like bone sialoprotein, osteopontin, osteonectin modulate nucleation and growth[4])